Tighter Inspection Provisions In Dingell Safety Bill Could Follow Ranbaxy Alert
This article was originally published in The Tan Sheet
Executive Summary
House Energy and Commerce Committee Chairman John Dingell likely will strengthen FDA mandates proposed in his evolving global drug safety bill in light of the agency's import alert for Ranbaxy products, including an OTC drug
You may also be interested in...
Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps
FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing
Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps
FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing
Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps
FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing